Portfolio Philosophy – from experience
- It’s all about the people.
- Bet on the jockey, not the horse.
- Allow twice as much time as you initially believe is required to achieve success.
- Don’t be surprised by surprises but learn from them.
MBA is an angel investor and the MBA Technology Investment Portfolio comprises early stage technology firms including biotechnology, medical devices, intelligent building systems, environmentally friendly packaging, food processing, green construction materials and parallel/serial computing. These firms are explained in more detail below.
Clera Inc. is a world leading private drug discovery and development company creating better medicines for aging related illness of the mind.
Clera is one of the few private drug discovery and development firms in the world with a wholly owned multiple clinical and pre-clinical drug pipeline targeting aging related illness of the mind.
Clera is targeting the massive aging related markets of Parkinson’s disease, cognition, Alzheimer’s and depression. These markets are currently served by drugs which work poorly and have terrible side-effects.
Clera is developing better drugs with little to no side effects and currently has four drug programs with multiple compounds in various stages of development.
Clera has completed two successful Phase IIa clinical trials, in Parkinson’s and depression/cognition. The Parkinson’s trial yielded statistically significant results in patients with mild to moderate Parkinson’s. In the depression trial, Clera’s antidepressant showed improvement over placebo and demonstrated significant promise in the secondary tested indication of cognition.
Clera has also created MIUN Inc to purchase and in-licence a Phase III drug.
Daiya makes dairy-free eating a joy. From the ooey gooey goodness of a grilled cheese to the rich and creamy taste of fruit-kissed yogurt, all our products taste great. And that makes you feel great.
Dairy is such a cultural staple and widely enjoyed in so many ways: on its own, in simple dishes or as part of a complex creation. Our plant-based alternatives provide the delicious characteristics you desire. Whether you suffer from allergies, are dairy-intolerant, living vegan or simply choosing a healthier lifestyle, Daiya is the perfect choice.
DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies.
Our lead product candidate, VAL-083, is a first-in-class small molecule chemotherapy that is currently being evaluated in a Phase 2 clinical trial for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 as a therapy for front-line GBM and solid tumors including non-small cell lung cancer (NSCLC) and ovarian cancer.
DelMar has also acquired certain exclusive commercial rights in China where VAL-083 is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer.
DelMar is dedicated to benefiting patients and creating shareholder value by rapidly developing and commercializing anti-cancer therapies in cancer indications where patients have failed or are unlikely to respond to modern therapy.
G-Pak is the first Keurig-compatible single serve coffee pod made from readily renewable materials and is 100 percent compostable. The innovative use of readily renewable materials combined with a dynamic design maintains the taste and integrity of the coffee. We provide a rich, great tasting, fully compostable product that will satisfy the consumer’s desire to brew a single-serve hot beverage in a sustainable and environmentally friendly way.
In 2012, entrepreneur Darren Footz began to realize the negative environmental impact created by single serve coffee pods, primarily K-Cups. Since then, he has been tirelessly committed to developing and commercializing the world’s first 100 percent compostable single-serve coffee pod. Darren’s industry experience, knowledge, and proven track record as a business leader has helped him in his pursuit to develop the revolutionary pod. The pod is the first Keurig-compatible single serve coffee pod made from readily renewable materials and is 100 percent compostable. The innovative use of readily renewable materials combined with a dynamic design maintains the taste and integrity of the coffee. We provide a rich, great tasting, fully compostable product that will satisfy the consumer’s desire to brew a single-serve hot beverage in a sustainable and environmentally friendly way.
Just BioFiber is an innovative building materials company that has developed a patented, sustainable, modular block, building system, which combines environmental benefits with structural integrity and competitive cost in the global market.
The technologies optimize the use of hemp and lime in building blocks that offer exceptionally high insulation, noise attenuation, structural and carbon capture levels.
The blocks can be used in all forms of building construction.
The Company has finalized the product development and intends to establish a production facility in the Calgary area with annual production capacity of 3.0 million building blocks.
Until MuscleSound, the ability to measure muscle health on a complete, immediate and non-invasive manner did not exist. MuscleSound brings this technology to markets including sports/fitness, healthcare, military, animal health and much more.
MuscleSound was formed in, 2011. The science behind MuscleSound was developed by Dr. Iñigo San Millán and Dr. John Hill when working with professional cyclists, they discovered that they could see glycogen through the use of everyday ultrasound. To further develop this breakthrough technology, Drs. San Millán and Hill teamed with Stephen Kurtz to build a delivery system to market their new product to potential customers.
Due to a passion for distance running and an interest in fitness and sports science, Mr.Kurtz was introduced to Drs. San Millán and Hill shortly after their discovery. Mr. Kurtz immediately saw the potential value in non-invasive muscle glycogen measurement and began exploring potential business applications. Kurtz and Drs. San Millán and Hill further advanced MuscleSound with the intention of selling this muscle glycogen technology to the sports and medical markets.
By developing software to read ultrasound images, MuscleSound was able to provide a customer ready product to the market in late 2013. In May and July of 2014 independent validation studies of MuscleSound (directly comparing to muscle biopsies to measure glycogen levels) were completed at Appalachian State University and the University of Colorado Medical Center. The publications of these two studies from highly reputable sources proved to be extremely valuable in gaining acceptance and legitimacy with the training and medical staffs of many professional, Olympic and collegiate sports teams.
In 2013, MuscleSound was issued three patents by the United States Patent and Trademark Office covering the use of ultrasound to measure muscle glycogen and related proprietary software. The Company has also received US Trademarks protecting its name and visual depiction. In 2014 MuscleSound developed technology to measure body composition using ultrasound and has applied for a patent for this unique application.
Optigo Networks offers an elegant networking solution designed specifically for modern intelligent buildings. Optigo Connect™ building network solution offers the perfect balance of security, reach, simplicity and bandwidth using low-power and low-profile products. With Optigo Connect™, all building IP controllers and IP appliances can be connected with minimal wiring and equipment. All network management can be performed from a single interface. Plus, network control and monitoring can be integrated into the building management system alongside all the other advanced building information and control using Optigo’s application programming interface (API).
Building automation is getting more sophisticated and powerful, driving big improvements to operational costs, energy efficiency and tenant comfort. With building control systems transitioning to IP, the challenge becomes how to connect all these controllers and smart devices in an efficient, effective and secure manner. Optigo Networks offers a unique solution capable of securely connecting all IP-enabled building devices, thus protecting the building from threats.
CCTV & Access Control
Optigo Networks connects security and access control systems, while protecting your building from threats. With security systems transitioning from analog to IP, the challenge becomes how to connect all the cameras and access control systems in a secure and effective manner.
In the race to deploy smart meters, utility and energy management companies are struggling with wireless technologies (e.g. ZigBee, wi-fi, Bluetooth, OTA, etc.). Connectivity and coverage issues continue to impede deployment of these wireless smart meter networks.
Optigo Networks’ advanced connectivity platform offers secure and reliable connectivity for energy and utility management for smart meter applications. Connectivity can be between buildings, offices and residences, or anywhere within an 8km radius of the central ONS-S2 Smart Aggregation Switch. Optigo’s solution reduces wiring requirements over other wired alternatives, is immune to electrical interference, is expandable and requires no additional network management.
PHEMI Systems Corporation is a big data warehouse company that lets organizations easily access and mine any variety of data at any volume to drive insights that lower costs, improve outcomes, and allow better decisions faster.
With an industry-pioneering approach to privacy, security, and governance, PHEMI protects privacy and ensures legitimate use of data to drive continuous improvement and help organizations meet compliance and governance requirements. An organizational ambassador for Privacy by Design, PHEMI brings both privacy and performance to big data solutions, along with the data management and control formerly only afforded by traditional enterprise data warehouses.
Headquartered in Vancouver, BC, the PHEMI team has a strong heritage in big data technologies, data networking, security, supercomputing, and IP service delivery.
Terramera is replacing conventional chemical pesticides with high performance plant based products for agriculture, the pest control industry and consumer use.
We are developing products to replace conventional chemical treatments with highly effective plant based pesticides for crop protection and crop health.
Proof® is a revolutionary EPA registered product with 100% pest kill rate offering an environmentally friendly and safer way to protect yourself.
Cirkil® is the only EPA registered biopesticide proven to effectively control bedbugs and the only such product known to be effective against eggs.
We offer Cold Pressed Neem Oil and partner with products in the agriculture, human health and cosmetics industries.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology.
Unlike previous generations of antibody therapies, XBiotech’s True Human™ antibodies are 100 percent human, derived from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human™ antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is currently advancing a robust pipeline of antibody therapies to exceed the standards of care in oncology, inflammatory conditions and infectious diseases. The Company’s broad pipeline of True Human™ antibodies are able to potentially deliver unmatched safety and efficacy because they are cloned directly from individual donors who possess natural immunity against certain targeted diseases. As such, True Human™ antibodies retain their natural physiology and tolerance profile, having passed the rigors of immune selection in the body.
XBiotech’s lead product, Xilonix™, is a potential breakthrough antibody therapy for patients with advanced colorectal cancer. Xilonix™ is in Phase III clinical trials in the United States with a Fast Track designation by the U.S. Food and Drug Administration (FDA). In Europe, Xilonix™ Phase III clinical trials have been completed, and the therapy is under accelerated review following the validation of its Market Authorization Application by the European Medicines Agency (EMA).
Xilonix™ specifically targets and neutralizes interleukin-1 alpha (IL-1 α), a molecule known to promote angiogenesis, growth and spread of tumors, as well as mediate symptoms such as metabolic dysregulation, fatigue and anxiety associated with advanced cancer.